Get on board if you aren't already. Time to take the ride up.
- News -
SUNRISE, FL--(Marketwired - Jul 24, 2014) - Bioheart, Inc. (OTCQB: BHRT) announced today that it has completed the world's first combination stem cell treatment with Magnum Cell Therapies (Magnum) in Honduras. A patient with congestive heart failure has been treated with a combination of AdipoCell™ or adipose derived stem cells and MyoCell® or muscle derived stem cells.
Sentiment: Strong Buy
My guess is that someone must think the stock is worth at least 4 cents per share. Also seems to free up management to look for some other forms of financing.
SUNRISE, FL--(Marketwired - Mar 26, 2014) - Bioheart, Inc. (OTCQB: BHRT), a biotechnology company focused on the discovery, development and commercialization of autologous cell therapies, announced that it will enroll patients in a new study for degenerative disc disease (DDD). The study will enroll up to 100 patients to determine the safety and efficacy of adipose derived stem cells or AdipoCell™ in patients with DDD.
Robert Silbert, MD of Physical Medicine/Rehab Associates in Indianapolis, Indiana is the principal investigator for the study. "Degenerative disc disease can be debilitating for many patients. Regenerative medicine offers new hope for these patients. It may stop or reverse the pain, disability, and the loss of material between the vertebrae," said Dr. Silbert.
SUNRISE, FL--(Marketwired - Mar 25, 2014) - Bioheart, Inc. (OTCQB: BHRT), a biotechnology company focused on the discovery, development and commercialization of autologous cell therapies, announced that Mike Tomás, President and CEO, has been named as one of the top 100 technology leaders on eMerge Americas Techweek100 Miami 2014.
SUNRISE, FL--(Marketwired - Mar 21, 2014) - Bioheart, Inc. ( OTCQB : BHRT ), a biotechnology company focused on the discovery, development and commercialization of autologous cell therapies, announced that it will present at the 31 st American Association of Orthopedic Medicine Annual Conference (AAOM) Conference and Scientific Seminar.
From CDC - Medical Tourism: .... Going Abroad for Medical Care
"Medical tourism" refers to traveling to another country for medical care. It's estimated that up to 750,000 US residents travel abroad for care each year. Many people who travel for care do so because treatment is much cheaper in another country. In addition, a large number of medical tourists are immigrants to the United States returning to their home country for care. The most common procedures that people undergo on medical tourism trips include cosmetic surgery, dentistry, and heart surgery.
It was nice to see you just created your profile on Wednesday to post here. Or are you also posting under another profile basher boy? - ilovetosueyou - Member since: Mar 12, 2014
IMO she's cute, and smart:
SUNRISE, FL--(Marketwire - Mar 12, 2013) - Bioheart Inc. (OTCQB: BHRT) announced that Bioheart's Chief Science Officer, Kristin Comella was named to the 50 most influential people on stem cells. The World Stem Cell Regenerative Medicine Congress asked the international stem cell community to compile a comprehensive list of the top 50. These personalities were picked based on their career achievements and dedication to the field of regenerative medicine. Ms. Comella debuted at #24 on the list.
She's a hotty, and one smart cookie too. Here's her profile:
On March 12, 2013, Kristin Comella was appointed to serve as a member of our Board of Directors. Ms. Comella was appointed Chief Scientific Officer in September 2010. Ms. Comella has served as our Vice President of R&D and Corporate Development since December 2008 and has played a major role in managing our product development, manufacturing and quality systems since joining Bioheart in 2004. Ms. Comella has 15 years of industry experience with expertise in regenerative medicine, training and education, research and product development, and currently serves on multiple advisory boards in the stem cell arena. Ms. Comella has over fifteen years of cell culturing experience including building and managing the stem cell laboratory at Tulane University's Center for Gene Therapy and developing stem cell therapies for osteoarthritis at Osiris Therapeutics. Ms. Comella holds an M.S. in Chemical Engineering from The Ohio State University and a B.S. in Chemical Engineering from the University of South Florida
'To Bash. Chiefly British, Canadian. To hurl harsh verbal abuse at.' - okay nitwit - or do you need nitwit defined too? - obviously we have opposing points of view.